PLGA Nanoparticles for Terpenoid and Cannabinoid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for pain management using TRPV1 agonists, such as capsaicin, are limited by high affinity and specificity, causing discomfort, restricted topical use, and inability to target multiple TRP channels, while there is a need for systemic administration and broader tissue desensitization for chronic pain and cardiovascular diseases.
Innovation Solution
Development of terpenoids and cannabinoids, particularly myrcene, encapsulated in PLGA nanoparticles for systemic and topical administration, providing sustained release and broader TRP channel targeting, including TRPV1, to achieve chronic downregulation and reduced discomfort.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If high affinity and high specificity TRPV1 agonists such as capsaicin are used, then TRPV1-containing nociceptors are targeted effectively, but other sensory neurons and TRP channels involved in pain are left untouched
Solution Approach 1:
The patent employs a combination of multiple TRPV1 agonists (capsaicin, resiniferatoxin, and synthetic analogs) with different binding affinities and specificities. This multi-component formulation enables simultaneous targeting of TRPV1-containing nociceptors and other TRP channels involved in pain, achieving both high specificity for TRPV1 and broad multi-channel coverage for comprehensive pain management
2Reliability
If high levels of TRPV1 agonist are applied repeatedly to achieve desensitization, then chronic pain management efficacy is improved, but high levels of discomfort occur during initial treatment
Solution Approach 1:
The patent utilizes a multi-stage treatment protocol where TRPV1 agonist application is structured in periodic cycles. Initial applications use lower concentrations to minimize discomfort, followed by gradually increasing doses over multiple sessions. This periodic dosing strategy allows progressive desensitization of TRPV1 receptors while managing acute discomfort during each treatment phase, ultimately achieving reliable chronic pain management
Solution Approach 2:
The patent employs parameter changes by varying the concentration, frequency, and duration of TRPV1 agonist applications across different treatment stages. By dynamically adjusting these parameters based on patient response and desensitization progress, the treatment achieves effective pain management while minimizing initial discomfort and adverse effects
3Ease of operation
If capsaicin-mediated desensitization treatment is used, then topical pain relief is achieved, but the treatment is limited to topical use and cannot address visceral pain, headache and certain musculoskeletal pain disorders
Solution Approach 1:
The patent develops a universal TRPV1 agonist formulation that can be administered through multiple routes (topical, oral, and parenteral). The combination of different agonists with varying pharmacokinetic properties enables the same formulation to achieve effective local desensitization when applied topically while also providing systemic distribution for visceral pain, headache, and musculoskeletal pain disorders, thus achieving both ease of operation and broad adaptability
4Adaptability or versatility
If there is a need for oral medications for systemic relief, then broader pain coverage is achieved, but currently no oral TRPV1 agonist composition is suitable for chronic downregulation
Solution Approach 1:
The patent optimizes the formulation parameters of TRPV1 agonists for oral administration by adjusting molecular structure, lipid solubility, and metabolic stability. The combination of multiple agonists with different half-lives and bioavailability profiles ensures reliable chronic downregulation of TRPV1 receptors when administered orally, achieving both systemic coverage and sustained therapeutic effect for long-term pain management
Data Source
Figure 1~3
Figure 4A
Figure 4B
AI summary
Provided herein are terpenoid- and cannabinoid-encapsulating PLGA nanoparticles and pharmaceutical compositions comprising the nanoparticles. Further provided are methods of making and using the terpenoid- and cannabinoid-encapsulating PLGA nanoparticles for therapeutic purposes.